

CytoDyn Inc.  
Form 8-K  
January 31, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): January 31, 2019**

**CytoDyn Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**000-49908**  
**(SEC**  
  
**File Number)**

**83-1887078**  
**(I.R.S. Employer**  
  
**Identification No.)**

**1111 Main Street, Suite 660**

**Vancouver, Washington**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (360) 980-8524**

**98660**

**(Zip Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01. Entry into a Material Definitive Agreement.**

On January 31, 2019, CytoDyn Inc. (the **Company**) entered into Subscription Agreements (the **Subscription Agreements**) with certain investors (the **Investors**) for the sale by the Company of 5,886,480 shares (the **Common Shares**) of the Company's common stock, par value \$0.001 per share (the **Common Stock**), in a registered direct offering (the **Offering**). The Investors in the Offering also received warrants to purchase 2,943,240 shares of Common Stock (the **Warrants**). Each share of Common Stock was sold together with one half of one Warrant to purchase one share of Common Stock for a combined purchase price of \$0.50.

The aggregate gross proceeds for the sale of the Common Shares and Warrants will be approximately \$2.9 million. Subject to certain ownership limitations, the Warrants will be exercisable commencing on the issuance date at an exercise price equal to \$0.50 per share of Common Stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the date of issuance. The closing of the sales of these securities under the Subscription Agreements is expected to occur on or about January 31, 2019.

The net proceeds to the Company from the transactions, after deducting the fees and expenses of the Placement Agent, as defined below (not including the Placement Agent Warrants, as defined below), the Company's estimated offering expenses, and excluding the proceeds, if any, from the exercise of the Warrants, are expected to be approximately \$2.6 million. The Company intends to use the net proceeds from the transactions to fund clinical trials for its lead product candidate and for general corporate purposes.

The securities sold in the Offering were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the **SEC**) on February 23, 2018 and subsequently declared effective on March 7, 2018 (File No. 333-223195) (the **Registration Statement**), and the base prospectus dated as of March 7, 2018 contained therein. The Company will file a prospectus supplement with the SEC in connection with the sale of the securities.

The representations, warranties and covenants contained in the Subscription Agreements were made solely for the benefit of the parties to the Subscription Agreements. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Subscription Agreements and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the forms of the Subscription Agreements are included with this filing only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Subscription Agreements, which subsequent information may or may not be fully reflected in public disclosures.

Pursuant to the Placement Agent Agreement, dated as of December 31, 2018 (the **Placement Agent Agreement**) with Paulson Investment Company, LLC (the **Placement Agent**), the Company has agreed to pay the Placement Agent a cash fee equal to 9% of the gross proceeds received by the Company from investors in the Offering, as well as a one-time non-accountable expense fee of \$35,000 for aggregate expenses incurred collectively in the Offering. Pursuant to the Placement Agent Agreement, the Company also agreed to grant to the Placement Agent or its designees warrants to purchase up to 9% of the aggregate number of shares sold to qualified investors in the Offering at an exercise price of \$0.50 per share (the **Placement Agent Warrants**). The Placement Agent Warrants provide for cashless exercise. The Placement Agent Agreement has indemnity and other customary provisions for transactions of this nature. The Placement Agent Warrants and the shares issuable upon exercise of the Placement Agent Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. The

Edgar Filing: CytoDyn Inc. - Form 8-K

Placement Agent Agreement is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The forms of Warrant and Subscription Agreement are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.

The legal opinion and consent of Lowenstein Sandler LLP relating to the securities are filed as Exhibit 5.1 to this Current Report on Form 8-K.

**Item 3.02. Unregistered Sales of Equity Securities.**

See Item 1.01 with respect to the Placement Agent Warrants.

In addition, in its Current Report on Form 8-K filed January 30, 2018 (the "Prior 8-K"), the Company previously disclosed the issuance on January 30, 2018, to an accredited investor, of a warrant to purchase an aggregate of 5,000,000 shares of Common Stock, in connection with the sale of a secured convertible promissory note to that same investor. A copy of that warrant is filed as Exhibit 4.2 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

**Exhibit**

<b>(d)</b>	<b>No.</b>	<b>Description.</b>
	4.1	<u>Form of Warrant Agreement.</u>
	4.2	<u>Convertible Promissory Note Warrant Agreement</u>
	5.1	<u>Opinion of Lowenstein Sandler LLP.</u>
	10.1	<u>Form of Subscription Agreement.</u>
	10.2	<u>Placement Agent Agreement.</u>
	23.1	<u>Consent of Lowenstein Sandler LLP (included in the opinion of Lowenstein Sandler LLP as Exhibit 5.1).</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn Inc.

January 31, 2019

By: */s/ Michael D. Mulholland*  
Name: Michael D. Mulholland  
Title: Chief Financial Officer